Aldoxorubicine

阿多比星

Report date: 2024/12/12 20:00:07
NME

Base Information

Drug NameAldoxorubicine
Drug Alias NameAldoxorubicin Hydrochloride阿多索比星阿多柔比星Doxorubicin-6-maleimidocaproyl hydrazoneTumour-targeted doxorubicin conjugate (LadRx Corporation) +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitorsReactive oxygen species stimulants
TargetsDNATopoisomerase IIReactive oxygen species
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunitybio IncXoma CorpCytrx Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[15] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG